Cytokine-induced killer (CIK) cells, defined as heterogeneous cells comprising CD3+CD56- T cells, CD3-CD56+ NK cells, and CD3+CD56+ natural killer T (NKT) cells, are also one of the hottest strategies that possess the potential to combat cancer by immunotherapy. The gene discussed is NCAM1; the disease is cancer.